This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie.

Xxx galfrie-18Xxx galfrie-14

Ever since monoclonal antibodies were produced in 1975 with mouse myeloma cells there has been interest in developing human myeloma cultures for the production of monoclonal antibodies.

However, despite multiple attempts, no human myeloma line suitable for hybridoma production has been described.

Here we report the derivation of a hypoxanthine–aminopterin–thymidine-sensitive and ouabain-resistant human myeloma cell line (Karpas 707H) that contains unique genetic markers.

We show that this line is useful for the generation of stable human hybridomas.

If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly.Below are the most common reasons: This site uses cookies to improve performance by remembering that you are logged in when you go from page to page.To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.It can easily be fused with ouabain-sensitive Epstein–Barr virus-transformed cells as well as with fresh tonsil and blood lymphocytes, giving rise to stable hybrids that continuously secrete very large quantities of human immunoglobulins.The derived hybrids do not lose immunoglobulin secretion over many months of continuous growth.The availability of this cell line should enable the The technique for the production of monoclonal antibodies was a culmination of a range of experimental studies with murine myeloma cell lines (1, 2).